BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 20421445)

  • 1. Breakthrough invasive candidiasis in patients on micafungin.
    Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
    J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous Mutational Frequency and
    Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
    Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
    Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
    Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
    Astvad KM; Perlin DS; Johansen HK; Jensen RH; Arendrup MC
    Antimicrob Agents Chemother; 2013 Jan; 57(1):177-82. PubMed ID: 23089746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
    Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
    Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
    Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
    J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
    Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
    J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
    Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
    Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
    Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.